Tripartite competition on COPD markets.

Published: 2003-12-15 07:00:00

Updated: 2003-12-15 07:00:00

The business interests in the chronic obstructive pulmonary disease (COPD) therapy is surging up slowly to the market and very competitive by 3 big foreign drug corporations, AstraZeneca, GSK and Boehringer/Pfizer.

COPD is a chronic obstructive respiratory tract disorder with symptoms of cough...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK